Nineteen structural analogs of 1-methyl- Studies over the past 5 years in our laboratories and by others have provided substantial support for the hypothesis that the expression of the neurotoxicity of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP) and the Parkinsonism it produces involves the following steps, all of which occur in the central nervous system. The initial bioactivation of M1PTP is catalyzed by monoamine oxidase (MAO), yielding 1-methyl-4-phenylpyridinium (MPP+) as the ultimate oxidation product (1, 2). In the case of 2'-substituted neurotoxic analogs of MPTP, part or all of the bioactivation is mediated by 4 The present paper concentrates on the terminal events leading to nigrostriatal cell death: the inhibition of NADH oxidation in mitochondria and in inverted inner membranes by MPP+ analogs and the energy-dependent accumulation of some of these analogs by intact mitochondria. The experiments reported may shed light not only on the mechanism of site 1 inhibition of mitochondrial respiration by the bioactivation products of MPTP but also on the nature of the inhibition site that MPP+ shares with rotenone, piericidin A, and barbiturates (10).
inhibit the mitochondrial oxidation of NAD+-linked substrates and the aerobic oxidation of NADH in inner membrane preparations from cardiac mitochondria. In the majority of cases, a good correlation was found between the two inhibition effects monitored. A few compounds were effective inhibitors of NADH oxidase but had only marginal effects on mitochondrial respiration. From studies of their accumulation by mitochondria, it appears likely that the latter compounds are not effectively concentrated by intact mitochondria by the electrical gradient and, in part for this reason, cannot reach sufficiently high concentrations at the appropriate binding site of NADH dehydrogenase. In addition, evidence is presented that the penetration of pyridinium analogs to the inhibition site in the NADH dehydrogenase complex may also be rate limiting. The data support the thesis that, for a substituted tetrahydropyridine to be acutely neurotoxic, its pyridinium oxidation product must be actively accumulated in the mitochondria and must inhibit NADH-ubiquinone oxidoreductase in its membrane environment.
Studies over the past 5 years in our laboratories and by others have provided substantial support for the hypothesis that the expression of the neurotoxicity of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP) and the Parkinsonism it produces involves the following steps, all of which occur in the central nervous system. The initial bioactivation of M1PTP is catalyzed by monoamine oxidase (MAO), yielding 1-methyl-4-phenylpyridinium (MPP+) as the ultimate oxidation product (1, 2) . In the case of 2'-substituted neurotoxic analogs of MPTP, part or all of the bioactivation is mediated by 4) . The MPP+ is then concentrated by the dopamine reuptake system and reaches the nigrostriatal neurons (5), where it equilibrates across the mitochondrial inner membrane in response to the electrical gradient (6, 7) . When the concentration of MPP+ in the mitochondria reaches levels of several millimolar, the reoxidation of NADH dehydrogenase by coenzyme Qjo is blocked; mitochondrial oxidation of NAD+-linked substrates and, hence, oxidative phosphorylation ceases (8) (9) (10) , and the resulting depletion of ATP causes collapse of the membrane and death of the nigrostriatal neurons. This is a simplified presentation of current views of the main events. Additional steps and alternative mechanisms may be involved (cf. ref. 7) .
The present paper concentrates on the terminal events leading to nigrostriatal cell death: the inhibition of NADH oxidation in mitochondria and in inverted inner membranes by MPP+ analogs and the energy-dependent accumulation of some of these analogs by intact mitochondria. The experiments reported may shed light not only on the mechanism of site 1 inhibition of mitochondrial respiration by the bioactivation products of MPTP but also on the nature of the inhibition site that MPP+ shares with rotenone, piericidin A, and barbiturates (10) .
MATERIALS AND METHODS Rat liver mitochondria were prepared from Sprague-Dawley rats by the mannitol procedure (11) . Oxygen consumption was measured polarographically. Since inhibition of mitochondrial respiration by MPP+ and its analogs is a function of both the concentration of inhibitor and the time of its preincubation with the mitochondria, IC50 or Ki values cannot be calculated in a simple manner. Hence, the following procedure was adopted. The mitochondria, buffer, and glutamate and malate were preincubated in the polarographic chamber at 250C with several concentrations of the inhibitor for times varying from 1.5 to 9 min. At that time, ADP was added and the rate of02 consumption was determined at 250C as described (9) . The results were then calculated from a plot of 1/time (min) of preincubation with the inhibitor required to reach 50% inhibition of state 3 respiration against the concentration of the inhibitor. The slope of the resulting line is K* in Table 1 . In instances in which the inhibition at all practical concentrations was so small even at 6 min as to make quantitative comparison impractical, the results were expressed as <<<MPP+-i.e., .far less effective than MPP'.
Electron transport particles (ETP) were isolated from beef heart mitochondria (12) . NADH oxidase activity was measured spectrophotometrically at 30°C with 02 as the terminal electron acceptor (10) . Energy-dependent accumulation of pyridinium compounds was measured by using tritiated inhibitors as described (6) .
Details of the synthesis of the MPP+ analogs have been published elsewhere (4, 13) .
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Comparison ofthe results ofthe two types of measurements shows a good correspondence in the inhibitory potencies ofthe various analogs tested, particularly if one considers that neither the IC50 value nor the K* value is a simple linear function of the concentration of inhibitor but, rather, both are empirical expressions. There were, however, notable exceptions in which compounds were considerably more effective as inhibitors of NADH oxidation in purified, submitochondrial particles but were less effective in inhibiting mitochondrial respiration-e.g., 1,1-dimethyl-4-phenyltetrahydropyridinium, 1-methyl-4-phenylpyrimidinium, 1-methyl-4-(2'-ethylphenyl)pyridinium, 1-methyl-4-(2'-chlorophenyl)pyridinium, 1-methyl-4-(4'-fluorophenyl)pyridinium, 1-propyl-4-phenylpyridinium, and 1-methyl-4-benzoylpyridinium (1,1-Me2-PTP+, MPPyrimidinium+, 2'-EtMPP+, 2'-CIMPP+, 4'-FMPP+, PPP+, and Me-4-BP+, respectively). Possible explanations of this discrepancy are that these compounds may be only slowly accumulated by the mitochondria and/or that their accessibility to the inhibition site in intact mitochondria is restricted. Evidence is presented below that both of these factors may play a role. No compound had a significantly better relative activity in intact mitochondria than it did in ETP. Table 1 further shows a striking inhibition ofboth NADH oxidase activity and mitochondrial respiration by N-dodecylpyridinium. This potent effect is almost certainly due to the lipophilic properties of the compound carrying it into all the respiratory complexes rather than it being a selective inhibitor of site 1 oxidation, since succinate oxidation is also inhibited by this analog.
We have previously reported (9, 10) on the inhibition of NADH oxidation by other MPP+ and MPTP analogs in inner membranes under conditions paralleling those in Table 1 . Among the compounds tested, 4-phenylpyridine was always the most potent NADH oxidase inhibitor, but it had only a modest effect on respiration. This is almost certainly due to the fact that it is not actively accumulated in the mitochondria by the electrochemical gradient, since it is uncharged at neutral pH. In decreasing order of effectiveness, 4-phenyl-1,2,3,6-tetrahydropyridine > MPTP > 4-phenylpiperidine (all uncharged at neutral pH) >> MPP+ > 1-methyl-2-phenylpyridinium = 1,2-dimethyl-4-phenyl-pyridinium were significantly inhibitory to NADH oxidase in ETP, whereas 1-methyl-3-phenylpyridinium, 1,2-dimethylpyridinium, and 1-methyl-4-t-butylpyridinium were not. These data (Table 1) add credence to the belief that there is significant structural specificity in the interaction of pyridine derivatives at the NADH dehydrogenase-CoQ junction.
To obtain evidence for the hypothesis that limited permeability across the inner membrane may account for the ineffectiveness of some MPP+ analogs as inhibitors ofNADH oxidation in intact mitochondria although they are effective in inverted membrane preparations, we measured the energydependent accumulation of MPP+ analogs by mitochondria. Fig. 1 shows that the 2'-Me-and 2'-Et-analogs are accumulated to almost the same extent by mitochondria as is MPP', in line with the fact that they are almost as inhibitory to mitochondrial respiration as MPP+ (Table 1 ). This agreement is particularly interesting, since 2'-EtMPP+ is 4 times more effective an inhibitor of NADH oxidation in ETP than is MPP+ itself. Clearly, in this instance, energized accumulation of the pyridinium compounds is a limiting factor. Similar experiments in Fig. 2 show that MPPyrimidinium' is concentrated by mitochondria only to a very small extent and thus probably never reaches the 0.7 mM intramitochondrial concentration needed to inhibit 50% of NADH oxidation in ETP (Table 1 ). This might explain why its inhibitory effect on intact mitochondrial respiration is very small. 4'-MeMPP+ and particularly 4'-FMPP+ are concentrated less effectively than MPP+, in accord with their lesser inhibitory power in mitochondria than in inverted membranes. The correspondence between the effects shown in Fig. 2 and in Table 1 is by no means perfect in these instances. It is emphasized, however, that neither the accumulation nor the mitochondrial inhibition data are linear functions of the concentration of the inhibitor. Thus, while they are reasonable indices of the effectiveness of different compounds as inhibitors of mitochondrial respiration or the degree to which they are accumulated at a given (50 AM) external concentration, the results from these two techniques permit only qualitative or semiquantitative comparison with each other. There is nevertheless a discrepancy in the behavior of 1,1-Me2-PTP+ in Fig. 2 . This compound is appreciably accumulated by the mitochondria, although not nearly as well as MPP'. It is marginally more effective than MPP+ as an inhibitor of NADH oxidation in ETP, but its inhibitory effect on mitochondria is too low to permit quantitative comparison with MPP+ (Table 1 ). This would suggest that additional factors may limit the effectiveness of such compounds as inhibitors of mitochondrial NADH oxidation.
Evidence for this concept was obtained in following up a recent report (14) that the tetraphenylboron anion (TPBaccelerates and potentiates the inhibition of mitochondrial respiration by MPP'. Earlier studies (15) (16) (17) had demonstrated that TPB-facilitates the movement of cations across membranes. This was also thought (14) to be the mechanism underlying the effect of TPB-in potentiating the effectiveness of MPP+ as an inhibitor. Fig. 3 shows that 10 Aum TPB- mitochondria, this effect is not as great as its action on mitochondrial respiration (Fig. 3) . In fact, as we have reported elsewhere (18) , at external concentrations of 50-500 /IM MPP+, 10 uM TPB-increases the intramitochondrial MPP+ concentration by the energy-dependent accumulation only 2.6-fold at apparent equilibrium. Higher concentrations of TPB-had no additional effect (18) . This is clearly insufficient to account for the dramatic effect demonstrated in Fig. 1 The NADH oxidase activity of ETP (0.02 mg/ml) was measured spectrophotometrically at 340 nm and 30'C in 50 mM NaPi (pH 7.5) in the presence of the inhibitor after preincubation with the inhibitor for 5 min at 0.8 mg of protein per ml.
of NADH oxidation by MPP+ in ETP (18) , since in this system the increased concentration resulting from mitochondrial accumulation is eliminated. TPB-potentiated the inhibition by MPP+, particularly at low concentrations of the inhibitor ( Table 2) . At 1 mM MPP+ alone, 15% inhibition was observed but in the presence ofTPB-the inhibition was 60%.
Together with its ability to enhance accumulation by the mitochondria, this effect could well account for the extraordinary effect of TPB-demonstrated in Fig. 3 . It was also noted that the effectiveness of4-phenylpyridine in blocking NADH oxidation in ETP was not affected by TPB- (18) . We have shown (19) that 4-phenylpyridine is a far more potent inhibitor of NADH oxidation in ETP or in complex I than is MPP+. Neutral pyridines may reach the hydrophobic inhibition site much more readily than charged compounds. Perhaps, by forming a neutral ion pair, TPBcircumvents the barrier to the access of charged compounds, rendering MPP+ and its congeners more effective inhibitors once inside the matrix. More extensive data and a discussion of the mechanism of the TPB-effect have been reported elsewhere (ref. 18; R.E.H., J. Hwang, S. Ofori, H. M. Geller, and W.J.N., unpublished data).
Applying these techniques to resolve the discrepancy observed with 1,1-Me2-PTP+ (Table 1) , Fig. 5 demonstrates the action of 10 ,um TPB-on the ADP-induced respiration rate (state 3 -state 4) with this inhibitor in the presence and absence of TPB-. Fig. 5 shows that without TPB-, 50% inhibition is not reached even at 20 mM external concentration of 1,1-Me2-PTP', almost 2 orders of magnitude higher than that required to block mitochondrial respiration. When 10 ,uM TPB-is present, 50% inhibition is reached at 0.06 mM 1,1-Me2-PTP'. This accounted for solely by the increase in the energy-dependent accumulation of the inhibitor in the matrix (data not shown). Thus, increased accessibility of the positively charged inhibitor to the hydrophobic binding site in the presence of 10 AM TPB-is likely to be a factor (Fig. 6) .
On the basis ofthe data presented, we suggest the following model to account for the effect of MPP+ analogs on mitochondrial respiration. For a pyridinium compound to be effective in blocking mitochondrial respiration and, hence, ATP synthesis, it must be positively charged at intracellular pH so that it is accumulated in the mitochondria as a result of the electrical gradient across the membrane. Once inside the matrix, it must reach the hydrophobic site of inhibition [where barbiturates, rotenone, and piericidins also block respiration (7, 19) ], to which charged molecules penetrate only slowly. Comparison of the effectiveness of pyridinium compounds as inhibitors in ETP and in intact mitochondria, in the presence and absence of TPB-, suggests that access to this site is even more restricted in intact mitochondria than in inverted membrane preparations, such as ETP and complex I. Thus, experiments with ETP or complex I reveal only the minimum requirement for the accessibility of a charged inhibitor to the "rotenone site." In intact mitochondria, additional restrictions may exist.
